Stock ZNTL ZENTALIS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Zentalis Pharmaceuticals, Inc. Stock

Equities

ZNTL

US98943L1070

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
10.98 USD -6.67% Intraday chart for Zentalis Pharmaceuticals, Inc. -12.40% -27.49%
Apr. 11 Zentalis Pharmaceuticals, Inc. Announces Executive Changes CI
Apr. 11 Zentalis Pharmaceuticals, Inc. Announces CFO Changes CI

Financials (USD)

Sales 2024 * 7M Sales 2025 * 4.28M Capitalization 779M
Net income 2024 * -270M Net income 2025 * -305M EV / Sales 2024 * 55 x
Net cash position 2024 * 394M Net cash position 2025 * 340M EV / Sales 2025 * 103 x
P/E ratio 2024 *
-3.02 x
P/E ratio 2025 *
-2.91 x
Employees 124
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.73%
More Fundamentals * Assessed data

Chart Zentalis Pharmaceuticals, Inc.

Dynamic Chart

Latest news about Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals, Inc. Announces Executive Changes CI
Zentalis Pharmaceuticals, Inc. Announces CFO Changes CI
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating That Wee1 Inhibitor Azenosertib Exerts Synergistic Anti-Tumor Activity with Kras(G12c) Inhibitors At Aacr Annual Meeting 2024 CI
Wedbush Raises Zentalis Pharmaceuticals' PT to $15 From $12, Tweaks Financing Assumptions, Says Still on Track to Share Multiple Azenosertib Datasets in 2024, 2025; Keeps Neutral Rating MT
Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Zentalis Pharmaceuticals Names Chief Medical Officer, Chief Business Officer MT
Zentalis Pharmaceuticals, Inc. Announces Executive Changes CI
Wedbush Raises Immunome's PT to $19 From $12 After Acquiring IM-1021 From Zentalis Pharmaceuticals, Maintains Outperform Rating MT
Immunome, Inc. and Zentalis Pharmaceuticals, Inc. Enter into an Exclusive, Worldwide License Agreement Under Which Immunome Has Licensed from Zentalis ZPC-21, A Preclinical Ror1 Antibody-Drug Conjugate CI
UBS Adjusts Zentalis Pharmaceuticals Price Target to $28 From $52, Maintains Buy Rating MT
Zentalis Pharmaceuticals Insider Bought Shares Worth $167,943, According to a Recent SEC Filing MT
Transcript : Zentalis Pharmaceuticals, Inc. - Special Call
North American Morning Briefing : Traders Await -2- DJ
Wedbush Downgrades Zentalis Pharmaceuticals to Neutral From Outperform After Announced Updates to Azenosertib Strategy in Platinumsensitive Ovarian Cancer; Cuts PT to $12 From $38 MT
Stifel Cuts Price Target on Zentalis Pharmaceuticals to $36 From $44, Maintains Buy Rating MT
More news

Latest transcript on Zentalis Pharmaceuticals, Inc.

Logo Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc. - Special Call
More transcripts

Analyst Recommendations on Zentalis Pharmaceuticals, Inc.

Wedbush Raises Zentalis Pharmaceuticals' PT to $15 From $12, Tweaks Financing Assumptions, Says Still on Track to Share Multiple Azenosertib Datasets in 2024, 2025; Keeps Neutral Rating MT
Wedbush Raises Immunome's PT to $19 From $12 After Acquiring IM-1021 From Zentalis Pharmaceuticals, Maintains Outperform Rating MT
UBS Adjusts Zentalis Pharmaceuticals Price Target to $28 From $52, Maintains Buy Rating MT
Wedbush Downgrades Zentalis Pharmaceuticals to Neutral From Outperform After Announced Updates to Azenosertib Strategy in Platinumsensitive Ovarian Cancer; Cuts PT to $12 From $38 MT
Stifel Cuts Price Target on Zentalis Pharmaceuticals to $36 From $44, Maintains Buy Rating MT
More recommendations

Press releases Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS Inhibitors at AACR Annual Meeting 2024 AQ
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024 AQ
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) AQ
Zentalis Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4) AQ
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) AQ
More press releases

Quotes and Performance

1 day-6.67%
1 week-12.40%
Current month-30.30%
1 month-19.11%
3 months-15.95%
6 months-31.34%
Current year-27.49%
More quotes

Highs and lows

1 week
10.39
Extreme 10.39
13.46
1 month
10.39
Extreme 10.39
16.27
Current year
10.39
Extreme 10.39
18.07
1 year
9.56
Extreme 9.56
31.46
3 years
9.56
Extreme 9.56
87.19
5 years
9.56
Extreme 9.56
87.19
10 years
9.56
Extreme 9.56
87.19
More quotes

Managers and Directors - Zentalis Pharmaceuticals, Inc.

Managers TitleAgeSince
Kimberly Blackwell CEO
 Chief Executive Officer 55 20-06-30
Cam Gallagher FOU
 Founder 54 14-12-22
Mark Lackner CTO
 Chief Tech/Sci/R&D Officer 56 22-10-16
Members of the board TitleAgeSince
Cam Gallagher FOU
 Founder 54 14-12-22
Diana Hausman CTO
 Chief Tech/Sci/R&D Officer 61 23-05-07
Karan Takhar BRD
 Director/Board Member 32 17-11-30
More insiders

ETFs positioned on Zentalis Pharmaceuticals, Inc.

Name Weight AuM 1st Jan change Investor Rating
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares -3x Short Biotechnology ETP Securities - USD
0.11% 0 M€ 0.00% -
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares 3x Long Biotechnology ETP Securities - USD
0.09% 0 M€ 0.00% -
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD ETF BMO MSCI Genomic Innovation Index ETF - CAD
0.07% 2 M€ -.--%
More ETFs positioned on Zentalis Pharmaceuticals, Inc.

Quotes

Date Price Change Volume
24-04-25 10.98 -6.67% 1,077,726
24-04-24 11.77 -6.36% 854,473
24-04-23 12.57 -3.31% 379,793
24-04-22 13 +0.31% 445,808
24-04-19 12.96 +3.35% 1,007,879

Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT

More quotes

Company Profile

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.
Sector
Biotechnology & Medical Research
Calendar
2024-05-01 - Q1 2024 Earnings Release (Projected)
Related indices
Russell 2000
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
10.98 USD
Average target price
35.6 USD
Spread / Average Target
+224.08%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ZENTALIS PHARMACEUTICALS, INC. Stock Zentalis Pharmaceuticals, Inc.
-27.49% 779M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.26% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.41% 95.71B
ARGENX SE Stock argenx SE
+0.79% 22.02B
BIONTECH SE Stock BioNTech SE
-17.84% 20.9B
GENMAB A/S Stock Genmab A/S
-11.11% 17.85B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.83% 16.21B
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.63% 15.52B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.55% 13.86B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+32.11% 12.04B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ZNTL Stock